Zhongzhi Pharmaceutical Holdings Limited

HKEX:3737.HK

0.92 (HKD) • At close November 12, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) HKD.

2024 Q22023 Q42023 Q22022 Q42022 Q22021 Q42021 Q22020 Q42020 Q22019 Q42019 Q22018 Q42018 Q22017 Q42017 Q22016 Q42016 Q22015 Q42015 Q22014 Q42014 Q22013 Q4
Revenue 1,088.426955.4841,094.328979.538846.397859.784886.716866.2737.676706.269635.913585.482556.668513.104431.53371.504358.968340.735347.301307.501288.064148.891
Cost of Revenue 461.38415.842419.365417.372341.214344.254340.898333.282279.505264.713243.231224.814213.915204.797178.456169.829161.205157.682155.276141.363133.92768.823
Gross Profit 627.046539.642674.963562.166505.183515.53545.818532.918458.171441.556392.682360.668342.753308.307253.074201.675197.763183.053192.025166.138154.13780.069
Gross Profit Ratio 0.5760.5650.6170.5740.5970.60.6160.6150.6210.6250.6180.6160.6160.6010.5860.5430.5510.5370.5530.540.5350.538
Reseach & Development Expenses 22.88629.43120.55128.36917.98121.54322.29129.88520.30426.32521.12330.76621.69821.18813.31311.1316.55813.6885.0967.2023.9822.796
General & Administrative Expenses 52.64552.93253.71955.54849.19855.82147.07847.90543.87239.36238.70643.434.40834.2430.17130.11825.94635.46525.4483019.72612.549
Selling & Marketing Expenses 448.475442.248444.956459.087349.997426.97398.749397.48297.534305.897257.445218.211234.089187.362167.642125.837119.71795.78883.90660.00270.09637.187
SG&A 501.12496.132498.675515.372399.195486.309445.827449.17341.406351.602296.151302.092268.497253.824198.047173.276160.608154.898109.354108.88790.05649.736
Other Expenses 0000000000000000000-70.437-52.35-52.35
Operating Expenses 524.006525.563507.131525.399408.741531.756464.916461.26367.467370.582311.984324.927286.366272.626204.513179.885159.092163.561111.553112.40392.9580.182
Operating Income 103.0414.079147.60816.57986.9273.12676.45157.42483.69365.45371.31429.96148.2432.62741.81916.37430.42413.53377.22150.15659.48128.953
Operating Income Ratio 0.0950.0150.1350.0170.1030.0040.0860.0660.1130.0930.1120.0510.0870.0640.0970.0440.0850.040.2220.1630.2060.194
Total Other Income Expenses Net 1.97925.68312.08218.6588.487-26.0213.70517.8828.2237.77711.39712.35611.2667.318.11911.6610.7017.5672.873.4841.689-0.251
Income Before Tax 105.01939.762167.81935.23795.414-18.34380.15675.30691.91673.2382.71142.31759.50639.93749.93828.03441.12521.180.09153.6461.1728.703
Income Before Tax Ratio 0.0960.0420.1530.0360.113-0.0210.090.0870.1250.1040.130.0720.1070.0780.1160.0750.1150.0620.2310.1740.2120.193
Income Tax Expense 20.76711.7831.6675.86117.8754.16513.6128.69119.91217.5323.7174.25612.4988.37511.4446.149.1472.66517.98714.76613.3567.031
Net Income 83.4427.875134.929.33977.048-14.4666.58866.52772.00555.758.99438.06147.00831.56238.49421.89431.97818.43562.10438.87447.81421.672
Net Income Ratio 0.0770.0290.1230.030.091-0.0170.0750.0770.0980.0790.0930.0650.0840.0620.0890.0590.0890.0540.1790.1260.1660.146
EPS 0.0990.0310.160.0350.091-0.020.0810.0810.0860.0670.0710.0440.0560.0390.0480.0270.040.0230.10.0650.080.036
EPS Diluted 0.0990.0330.160.0350.091-0.0170.0810.0810.0860.0670.0710.0460.0560.0390.0480.0270.040.0230.10.0650.080.036
EBITDA 117.92839.358175.46742.5111.37123.07596.63999.571104.12281.53284.95842.19960.24243.41753.39729.75238.69722.36384.4455.38566.29532.016
EBITDA Ratio 0.1080.0410.160.0430.1320.0270.1090.1150.1410.1150.1340.0720.1080.0850.1240.080.1080.0660.2430.180.230.215